Management of adult primary immune thrombocytopenia based on Japanese clinical guides.
Primary immune thrombocytopenia (also known as idiopathic thrombocytopenic purpura; ITP) is an autoimmune disorder characterized by isolated thrombocytopenia due to accelerated platelet destruction and impaired platelet production. The therapeutic goal of ITP is not to normalize the platelet count, but to elevate the platelet count to a safe range (above 30×103/µl) to minimize the risk of bleeding and to minimize the side effects of drugs such as corticosteroids and TPO receptor agonists (TPORAs). In 2011, TPORAs were approved for the management of refractory ITP in Japan. To announce the proper use of TPORAs, we have published a practical guide for the management of adult primary ITP and primary ITP during pregnancy in 2012 and 2014, respectively, as a study group of the Specific Disease Treatment Research Program for Intractable Diseases of the Ministry. Notably, Helicobacter pylori eradication was approved for the management of ITP in 2010 in Japan. Because there was no evidence based on the prospective randomized controlled trials regarding the management of ITP during pregnancy, we conducted several meetings to obtain a consensus among hematologists, obstetricians, pediatricians, and anesthesiologists. In this paper, I have reviewed the practical guides for the management of adult ITP.